{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:36:50Z","timestamp":1778661410867,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,3,10]],"date-time":"2010-03-10T00:00:00Z","timestamp":1268179200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s10875-010-9373-x","type":"journal-article","created":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T08:43:28Z","timestamp":1268124208000},"page":"442-448","source":"Crossref","is-referenced-by-count":20,"title":["Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen\u00ae, at Different Infusion Rates"],"prefix":"10.1007","volume":"30","author":[{"given":"John W.","family":"Sleasman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla M.","family":"Duff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Dunaway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail A.","family":"Rojavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,10]]},"reference":[{"key":"9373_CR1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0090-1229(82)90022-8","volume":"22","author":"AJ Ammann","year":"1982","unstructured":"Ammann AJ, Ashman RF, Buckley RH, Hardie WR, Krantmann HJ, Nelson J, et al. Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial. Clin Immunol Immunopathol. 1982;22:60\u20137.","journal-title":"Clin Immunol Immunopathol"},{"key":"9373_CR2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1056\/NEJM199107113250207","volume":"325","author":"RH Buckley","year":"1991","unstructured":"Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med. 1991;325:110\u20137.","journal-title":"N Engl J Med"},{"key":"9373_CR3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-101-4-435","volume":"101","author":"C Cunningham-Rundles","year":"1984","unstructured":"Cunningham-Rundles C, Siegal FP, Smithwick EM, Lion-Boule A, Cunningham-Rundles S, O'Malley J, et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med. 1984;101:435\u20139.","journal-title":"Ann Intern Med"},{"key":"9373_CR4","doi-asserted-by":"crossref","unstructured":"Cramer M, Frey R, Sebald A, Mazzoletti P, Meader W. Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen\u2122) stabilized with L-proline. Vox Sang. 2009;96:219\u201325.","DOI":"10.1111\/j.1423-0410.2008.01143.x"},{"key":"9373_CR5","doi-asserted-by":"crossref","unstructured":"Bolli R, Woodtli L, B\u00e4rtschi M, H\u00f6fferer L, Lerch P. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals (doi: 10.1016\/j.biologicals.2009.09.002 ) 2009.","DOI":"10.1016\/j.biologicals.2009.09.002"},{"issue":"Suppl. 1","key":"9373_CR6","first-page":"96","volume":"96","author":"R Bolli","year":"1999","unstructured":"Bolli R, Spycher MO, Br\u00fcgger R, W\u00fcst B, Gennari K. IgG-dimer formation in liquid immunoglobulin preparations is inhibited by nicotinamide and other amphiphilic compounds. J Autoimmun. 1999;96 Suppl 1:96.","journal-title":"J Autoimmun"},{"key":"9373_CR7","first-page":"312","volume-title":"Intravenous immunoglobulin research and therapy","author":"J Schnorf","year":"1996","unstructured":"Schnorf J, Arnet B, Burek-Kozlowska A, Gennari K, Rohner R, Sp\u00e4th PJ, et al. Laboratory parameters measured during infusion of immunoglobulin preparations for intravenous use and related to tolerability. In: Kazatchkine MD, Morell A, editors. Intravenous immunoglobulin research and therapy. New York: Parthenon; 1996. p. 312\u20133."},{"issue":"Suppl","key":"9373_CR8","first-page":"96","volume":"1","author":"MO Spycher","year":"1999","unstructured":"Spycher MO, Bolli R, Hodler G, Gennari K, Hubsch A, Sp\u00e4th P, et al. Well-tolerated liquid intravenous immunoglobulin G preparations (IVIG) have a low immunoglobulin G dimer (IgG-dimer) content. J Autoimmun. 1999;Suppl 1:96.","journal-title":"J Autoimmun"},{"key":"9373_CR9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10875-008-9231-2","volume":"29","author":"MR Stein","year":"2009","unstructured":"Stein MR, Nelson RP, Church JA, Wasserman RL, Borte M, Vermylen C, et al. Safety and efficacy of Privigen\u00ae, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29:137\u201344.","journal-title":"J Clin Immunol"},{"key":"9373_CR10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/ajh.20822","volume":"82","author":"JB Bussel","year":"2007","unstructured":"Bussel JB, Hanna K. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura. Am J Hematol. 2007;82:192\u20138.","journal-title":"Am J Hematol"},{"key":"9373_CR11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s10875-006-9014-6","volume":"26","author":"EW Gelfand","year":"2006","unstructured":"Gelfand EW, Hanna K. Safety and tolerability of increased rate of infusion of intravenous immunoglobulin G, 10% in antibody-deficient patients. J Clin Immunol. 2006;26:284\u201390.","journal-title":"J Clin Immunol"},{"key":"9373_CR12","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","volume":"117","author":"JS Orange","year":"2006","unstructured":"Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117:S525\u201353.","journal-title":"J Allergy Clin Immunol"},{"key":"9373_CR13","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/00129804-200605001-00001","volume":"29","author":"K Duff","year":"2006","unstructured":"Duff K. You can make a difference in the administration of intravenous immunoglobulin therapy. J Infus Nurs. 2006;29:S5\u201314.","journal-title":"J Infus Nurs"},{"key":"9373_CR14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00129804-200507000-00009","volume":"28","author":"E Murphy","year":"2005","unstructured":"Murphy E, Martin S, Patterson JV. Developing practice guidelines for the administration of intravenous immunoglobulin. J Infus Nurs. 2005;28:265\u201372.","journal-title":"J Infus Nurs"},{"key":"9373_CR15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0887-7963(03)00038-5","volume":"17","author":"LR Pierce","year":"2003","unstructured":"Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev. 2003;17:241\u201351.","journal-title":"Transfus Med Rev"},{"key":"9373_CR16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10875-007-9096-9","volume":"27","author":"M Berger","year":"2007","unstructured":"Berger M, Cunningham-Rundles C, Bonilla FA, Melamed I, Bichler J, Zenker O, et al. Carimune NF liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. J Clin Immunol. 2007;27:503\u20139.","journal-title":"J Clin Immunol"},{"key":"9373_CR17","unstructured":"Immune Globulin Intravenous (Human) Flebogamma 5%, Prescribing Information. Grifols S.A.; 2003."},{"key":"9373_CR18","unstructured":"Immune Globulin Intravenous (Human) 10% Gammagard Liquid Prescribing Information. Baxter Healthcare Corporation; 2005."},{"key":"9373_CR19","unstructured":"Immune Globulin Intravenous [Human] 10% Gamunex, Prescribing Information. Talecris Biotherapeutics, Inc.; 2005."},{"key":"9373_CR20","unstructured":"Immune Globulin Intravenous (Human) 5% Octagam, Prescribing Information. Octapharma AG; 2008."},{"key":"9373_CR21","first-page":"1","volume":"53","author":"ML Lindegren","year":"2004","unstructured":"Lindegren ML, Kobrynski L, Rasmussen SA, Moore CA, Grosse SD, Vanderford ML, et al. Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. MMWR Recomm Rep. 2004;53:1\u201329.","journal-title":"MMWR Recomm Rep"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-010-9373-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-010-9373-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-010-9373-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T04:10:07Z","timestamp":1559275807000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-010-9373-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,10]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["9373"],"URL":"https:\/\/doi.org\/10.1007\/s10875-010-9373-x","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,10]]}}}